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Introduction 
 Serine proteases are a large family of proteolytic enzymes which utilize a serine residue 
as a reactive nucleophile in the active site. Some of the more common serine proteases are 
chymotrypsin, trypsin, thrombin, human leukocyte elastase (HLE), human cathepsin G, and 
human cytomegalovirus protease (HCMV protease). The method of catalysis of the prototypical 
serine protease, chymotrypsin, is shown in figure 1. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1
10
: Catalytic Method of Chymotrypsin 
 
 Unregulated serine protease activity has been implicated in several common ailments, 
including rheumatoid arthritis, emphysema, pancreatitis, atherosclerosis, cystic fibrosis, and 
Alzheimer’s disease. Since serine proteases are responsible for the onset of such a wide range of 
diseases, there is an equivalent need for a large library of synthetic serine protease inhibitors to 
selectively counteract these conditions. To date, several serine protease inhibitors have been 
developed with reactive functionality,
1 
such as aldehydes, azapeptides, boronic acids, 
chloromethyl ketones, and chloropyrones to disrupt the enzyme’s proteolytic activity by trapping 
the reactive serine nucleophile. A common structural motif in many of these inhibitors has been 
the incorporation of reactive functionality into a peptide backbone. These molecules compete 
with natural substrate for binding sites in the enzyme’s active site, and utilize the reactive 
functionality to counteract enzyme activity by trapping the serine alcohol. In addition to these 
molecules, compounds which have incorporated the monocyclic -lactam into their structure 
have also been reported to inhibit some serine proteases. To date, monocyclic -lactam 
derivatives have been reported as inhibitors of HLE,
2,3,4
 human cathepsin G,
3
 -lactamase,5 
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bacterial leader peptidase,
6
 and HCMV protease.
7
 All of these reported monocyclic -lactam 
inhibitors take advantage of the reactivity of the -lactam ring, however, none of these 
previously synthesized inhibitors attempt to deliberately mimic the natural substrates of serine 
proteases. 
 The inhibitors proposed in this project will incorporate the reactive -lactam functionality 
into the peptide backbone of a serine protease substrate. Molecules with the general structure 
depicted in figure 2, will be synthesized and tested in an inhibition assay with chymotrypsin,
8 
the prototypical serine protease.  
 
 
 
 
 
 
Figure 2: Design of Monocyclic -lactam Peptidomimetics 
 
 These monocyclic -lactam inhibitors will theoretically be recognized by the serine 
protease as a substrate, and bind in a manner which places the -lactam at the active site  (figure 
3, page 7). In the active site, the -lactam will occupy the S1 subsite
9
, and the substituent 
attached to the N-1 nitrogen will occupy the S1' subsite, and extend in the direction of the 
carboxy terminus of a natural chymotrypsin substrate.  
 The -lactam ring is inherently a very reactive structure. The atoms in the ring are 
constrained to bond angles of 90
o
 by the four-membered ring. The sp
2
 hybridized trigonal planar 
carbon (C-2) desires a bond angle of 120
o
, but is constrained to 90
o
 by the ring. The other three 
atoms in the - lactam ring are sp3 hybridized (tetrahedral geometry) and have preferred bond 
angles of 109.5
o
. These atoms also experience a great deal of bond angle strain due to their 
inclusion in the -lactam ring.10 This bond angle strain makes the -lactam ring reactive, and 
susceptible to nucleophilic attack at the electrophilic C-2.   
 As indicated by figure 3, once the inhibitor is in the active site, the protease’s serine 
hydroxyl group will attack at position C-2 of the -lactam and open the reactive ring. However, 
the C-4 methylene of the -lactam will prevent the release of N-1 from the molecule. This will 
trap the enzyme in the acyl-enzyme intermediate form, which will be hydrolyzed slowly. In 
addition to the methylene bridge at C-4 holding the structure together, another reason for slow 
hydrolysis is the limited access of water into the crowded active site. As seen in figure 1, (page 
5) the decomposition of the acyl-enzyme intermediate is driven by the attack of a water 
molecule. With the residues attached to N-1 still in place due to the methylene bridge, the attack 
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by water will be sterically hindered, thus further slowing down the hydrolysis of the acyl-enzyme 
intermediate.   
 
 
 
 
 
 
 
 
Figure 3: Proposed Mode of Serine Protease Inhibition By Monocyclic -Lactams 
 
These inhibitors have been rationally designed to inhibit serine proteases by this mechanism, 
however, previous research involving -lactam type inhibitors of serine proteases,11,12 has shown 
that inhibitors sharing the same functionality often behave differently in enzyme assays. Because 
of this, the exact mode of inhibition of these compounds will need to be determined 
experimentally.  
 As mentioned previously, serine protease inhibitors have been designed by creating 
peptidomimetics which include reactive moieties such as aldehydes,
13
 boronic acids,
14
 
chloromethyl ketones,
15
 fluoroketones,
16
 -keto esters,17 or aza-peptides.18 Most of these 
reported inhibitors (shown in figure 4) have incorporated a reactive functionality at the carboxy 
terminus of the peptide. Because of this, these peptidomimetics can only become involved in 
attractive interactions on one side of the scissile bond.  The inhibitors synthesized in this project 
will be the first to incorporate the monocyclic -lactam functionality into a peptide backbone. 
Similar to the fluoroketones,
16(c)
 and aza-peptides,
18(b) 
the monocyclic
 -lactam peptidomimetics 
have the unique ability to exploit interactions with enzyme specificity pockets on both sides of 
the scissile bond.  
 
 
 
 
 
 
 
 
Figure 4: Rationally Designed Inhibitors of Serine Proteases 
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The groups which extend from both sides of the -lactam will interact with the active site like a 
natural peptide substrate of chymotrypsin. If the interactions with the enzyme’s active site are 
strongly attractive, the inhibitor should be effective against chymotrypsin. The scheme used to 
synthesize these inhibitors allows for the importance of these individual interactions to be 
explored in an incremental fashion. Once the initial inhibitor has been synthesized, 
accommodations in the synthesis can be made to alter all of the “R” groups ( figure 2, page 6). 
By comparing inhibitory constants from the various inhibitors, it will be possible to see which 
groups are the most important for inhibition, and a pharmacophore for these types of inhibitors 
could be developed. 
 Preliminary molecular 3-D modeling studies have indicated that, in most cases, a 
peptidomimetic containing the -lactam functionality is about 45 kilocalories per mol less stable 
than it’s straight chain peptide counterpart. These calculations are based on steric energy 
minimization calculations, and the energy difference seems reasonable. The introduction of the 
-lactam into the structure will limit some of the free rotation about the -bonds, and cause the 
steric energy to increase. 
 In addition, recent conformational studies,
19 
with peptidomimetic monocyclic -lactams 
have indicated that the most likely conformation of this type of structure is a -turn. The degree 
of -turn in the structure depends on the exact groups attached to the monocyclic -lactam core. 
The effect that the -turn conformation will have on the inhibitory properties of the proposed 
inhibitors will have to be ascertained directly through enzyme inhibitory studies.  
 If these rationally designed compounds are found to successfully inhibit chymotrypsin, 
the library of reactive functionality that can be used to combat serine protease activity will be 
expanded. Unlike many of their predecessors, these inhibitors will have the distinction of being 
able to exploit interactions with the enzyme on both sides of the scissile bond. 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
Results and Discussion 
 The first synthetic step was to assemble a fully protected monocyclic -lactam (3) in a 
three step process (Scheme 1). This fully protected monocyclic -lactam is the core from which 
all possible inhibitor targets are synthesized. Because this -lactam core is such an important 
intermediate in the synthetic pathway, the development of Scheme 1 was a major focus of this 
project.      
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: Synthetic Pathway to the Monocyclic -lactam Core 
 
 In the first step of Scheme 1, a hydroxamate serine derivative (1) was synthesized by the 
method of Miller et al,
20
 coupling N-tertbutoxycarbonyl L-serine (t-Boc-serine) to the 
hydroxylamine hydrochloride salt, HCl*H2NOBn. This nucleophilic substitution on an acyl 
group involves the attack of a nucleophile (HCl*H2NOBn) on the electrophilic carbon of the 
carbonyl from the carboxylic portion of t-Boc-serine. In order for this reaction to occur by this 
mechanism, the nucleophilic attack must be accompanied by the simultaneous departure of a 
leaving group, in this case, the hydroxyl group from the carboxylic acid would have to leave as a 
hydroxide anion. In general, strong bases are poor leaving groups, and weak bases are very good 
leaving groups.
10
 Because the hydroxide anion (OH
-
) is the prototypical strong base, it is 
therefore also a poor leaving group. 
 This obstacle is overcome by adding a coupling agent such as dicyclohexylcarbodiimide 
(DCC) to the reaction pot. Coupling reagents such as DCC will react with the free hydroxyl 
group of t-Boc-serine’s carboxy terminus. This reaction modifies the OH group, and creates a 
good leaving group in its place.
10
 The nucleophilic amine (HCl*H2NOBn) can then be added, 
and the reaction will proceed to yield the serine hydroxamate derivative (1). Early attempts of 
this reaction involved using the aforementioned DCC as the coupling reagent. Although DCC is 
 
 
10 
 
a relatively inexpensive and readily available reagent, it presents a logistical problem in the 
synthesis. When DCC is used as a coupling reagent, dicyclohexylurea (DCU) is generated as a 
side product. DCU precipitates as a white solid, which must be removed via filtration. Removing 
all of the accumulated DCU via filtration was not always an easy task, and DCU had a tendency 
to appear as a contaminant in ensuing reactions. This observation, accompanied by the fact that 
the yields were not as high as they should ideally be in the first step of a synthesis (60-70%) led 
to the exploration of other coupling reagents as an alternative. The next coupling reagent 
attempted was 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). EDC 
eliminated the precipitate problems that were inherent to DCC, however, the yields were still 
lower than expected (60%). It was concluded that the low yields were a result of factors other 
than the choice of carbodiimide coupling reagent.  
 Another aspect of this reaction that received considerable attention was the control of pH. 
Miller’s protocol10 performs this reaction in a pH range of 4-5. In order to maintain this pH 
range, careful consideration was taken. When the slightly acidic hydrochloride (HCl*H2NOBn) 
was added to the stirring solution of t-Boc serine, the pH value quickly decreased to 1.5. To 
bring the solution back to the desired pH range, 1M NaOH was added dropwise. Then, when 
EDC was added, and the reaction had commenced, the pH began to gradually increase. This is 
due to the anionic nitrogen formed on the carbodiimide during its reaction with t-Boc-serine. In 
addition to this, when the nucleophillic substitution takes place, the carbodiimide leaves as an 
anion. To maintain the desired pH range of 4-5, 1M HCl was added dropwise over the course of 
the reaction (monitored by pH meter). Since the anions are formed throughout the entire course 
of the reaction, it was necessary to closely monitor the reaction progress via pH meter and adjust 
the pH as necessary.  
 Despite choosing the correct carbodiimide coupling reagent and monitoring the pH of the 
reaction carefully, yields were still less than satisfactory (60-70%). One possible explanation for 
this was problems with the work up and isolation of the hydroxamate (1). The Miller protocol 
calls for a total of nine aqueous washes during the work up. It was suspected that some of the 
product may have been brought into the aqueous layer by THF (THF solvates the hydroxamate 
product, and is miscible with H2O) and lost during the washes. The solvent system, according to 
Miller’s protocol, should be a 1:2 mixture of THF:H2O. Based on the fact that the product (1) is 
soluble in THF, but insoluble in H2O, it was proposed that using less THF might cause 1 to 
precipitate from the solution as it is formed. As a modification to the Miller procedure, the 
reaction was run with a minimum amount of THF in the solvent mixture. As predicted, when the 
solvent mixture contained just enough THF to dissolve all of the reagents, hydroxamate 1 
precipitated as it formed. Upon completion, the white crystalline hydroxamate 1 was isolated via 
vacuum filtration in 90% yield. This compound needed no further purification as indicated by 
11 
 
TLC and melting point data. This highly reproducible protocol eliminated the need for the time 
consuming and difficult aqueous washes, and increased the average yield up to 90%, a very 
respectable yield for the first step in the synthetic pathway. 
 The next step in Scheme 1 is to cyclize hydroxamate 1 into the fully protected -lactam 
3.
 
This transformation occurs via an intramolecular SN2 reaction with the O-Benzyl protected 
nitrogen atom as the reactive nucleophile. For this reaction to occur, the leaving group would be 
the hydroxyl group from serine’s side chain. For reasons previously mentioned, a hydroxide 
anion is a very poor leaving group, which would need to be modified in order for the reaction to 
proceed. Since this is not a nucleophilic substitution on an acyl group, using a carbodiimide 
would not work to improve the
 
hydroxide anion as a leaving group. Instead, methanesulfonyl 
chloride (MsCl) is used. MsCl reacts with the alcohol (from 1) in a nucleophilic substitution 
reaction to form mesylate 2.
10
 A basic solvent, pyridine is used to neutralize the HCl that forms 
during the process. In this reaction, a poor leaving group, the hydroxide anion , is converted to 
the mesylate anion, a good leaving group. The reaction was run in pyridine, at 0
o
C, under 
anhydrous conditions. It is very important to note that anhydrous conditions must be strictly 
adhered to. The mesylate anion is a good enough leaving group to possibly facilitate a side 
reaction in the presence of H2O. If trace amounts of H2O enter the reaction vessel from the 
atmosphere, undried solvent, or undried glassware, the H2O would act as a nucleophile, and 
replace the mesylate anion via nucleophillic substitution. By this process, the reaction reverts 
back to the starting material, hydroxamate 1 as indicated below in figure 5. 
  
 
    
 
 
 
Figure 5: Decomposition of the Mesylate in the Presence of H2O 
 
 However, when the anhydrous protocol is followed, this reaction has proven to be the 
easiest in this synthetic pathway. Typically, this reaction produces the mesylate (2) in yields 
above 90%.  
 Now that a good leaving group has been created, an intramolecular SN2 cyclization can 
be run to yield the fully protected -lactam (3). A closer look into the mechanism of this reaction 
indicates why the O-benzyl group attached to the nucleophilic nitrogen atom is so vital to this 
reaction. In order for this reaction to be spontaneous, the nucleophilicity of the amine must be 
enhanced. The O-benzyl group contributes to this enhancement in two ways.  
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 The first way is through a phenomenon known as the -effect.22 Whenever the atom 
adjacent to the attacking nucleophile contains one or more pairs of unshared electrons, the 
strength of the nucleophile is enhanced. There is currently no concrete evidence to explain why 
this occurs, but two ideas have been hypothesized. One is that the ground state of the nucleophile 
is destabilized by repulsions from the unshared electron pairs on the adjacent atom. The other 
theory is that the transition state of the reaction could be stabilized by the adjacent unshared 
electron pairs.
22
 Although neither of these explanations can currently be proven, the -effect is a 
phenomenon that has repeatedly been experimentally observed. In the case of this reaction, the 
two pairs of unshared electrons on the adjacent oxygen atom contribute to the enhanced 
nucleophilicity of the nitrogen atom. 
 The second, and most important contribution to the amine’s enhanced nucleophilicity is 
the fact that the O-benzyl group is an electron withdrawing group (EWG).
10
 In order for the 
amine to participate in the intramolecular SN2 reaction, it must be deprotonated (or the 
equilibrium must lie in favor of the deprotonated form). K2CO3 is the base used to achieve this 
deprotonation. However,  K2CO3 is a fairly weak base, and would not be strong enough to 
deprotonate an amide (not benzyloxy protected) (pKa~17). By adding the benzyloxy substituent 
to the amide, the pKa is reduced. The benzyloxy substituent withdraws electron density from the 
nitrogen atom. The reduced electron density of the nitrogen atom, due to the ability of the 
benzyloxy substituent to stabilize a negative charge, causes the pKa of the hydroxamate to 
decrease (pKa~6-10). In essence, the amine can now lose a proton more easily, because the anion 
will be stabilized. In the presence of  K2CO3, the equilibrium of the benzyloxy substituted amine 
lies in favor of its deprotonated form.     
 With the O-benzyl substitution the amine is sufficiently nucleophilic to take part in the 
intramolecular SN2 reaction. In addition, the incorporation of the methyl sulfonate ester (OMs) 
into the molecule has enhanced the efficiency of the leaving group. This reaction was facilitated 
by refluxing the mesylate (2) with K2CO3 in dried acetone under anhydrous conditions as 
indicated by the protocol of Floyd et al.
21
 Once again, the strict anhydrous environment was 
essential to the success of this reaction. As indicated in figure 5, mesylate 2 has a tendency to 
revert back to hydroxamate 1 in the presence of H2O.After aqueous work up and column 
chromatography, yields of-lactam 3 (the fully protected monobactam core) have been as good 
as 70-80%.  
 The only attempted modification to the reaction sequence was an attempt to transform 
hydroxamate 1 directly into 3 in a one step process.
23
 The hydroxamate was reacted with 1-1'- 
sulfonyldiimidazole and sodium hydride (NaH) in a solution of dimethylformamide at low 
temperature. TLC showed that the crude product contained a large number of impurities, but the 
presence of the product was not identified. Due to the large number of impurities present and the 
13 
 
unconfirmed presence of product, this reaction was not pursued any further in the pathway to the 
- lactam core. 
 Once 3 had been obtained in high purity and yield via Scheme 1, the next step in the 
synthesis was to deprotect and extend 3 on both sides of the scissile bond. Previous attempts in 
the lab focused on removing the t-Butoxycarbonyl group from 3 and coupling other residues to 
the resulting free amine. In all cases these reactions were unsuccessful due to a suspected 
opening of the strained - lactam ring. The theoretical explanation for this draws on concepts 
that have previously been developed. he N-1 nitrogen atom of 3 is benzyloxy protected. As 
mentioned previously, the benzyloxy substituent reduces the pka of N-1, thereby making it a 
weaker base. Weaker bases have been known to be good leaving groups in reactions. The strong 
ability of N-1 to leave, causes the bond between N-1 and C-2 in the -lactam to become 
weakened. In attempts to remove the t-Boc group from 3, this labile bond is broken, destroying 
the -lactam ring. 
 This evidence caused the focus of the synthesis to shift toward the removal of the 
benzyloxy protecting group from 3. This reaction is the first step in Scheme 2, the elaboration of 
the monocyclic -lactam core, and it has proven to be the most difficult reaction in the synthesis. 
Difficulties with this reaction have caused it to become the major focus of most recent research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: The Elaboration of the Monocyclic -lactam Core 
 
 Based on the work of Chiara et al,
24
 -lactam 3 was reacted with a 0.1 M solution of the 
Lewis acid samarium (II) iodide (SmI2) and deoxygenated H2O in THF. Although the exact 
reaction mechanism has not been experimentally determined, it is proposed to be a free radical 
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process. Early attempts of this reaction were successful, but with low yields (40-50%). Yields 
appeared to be higher when a freshly opened bottle of SmI2 was used as opposed to when SmI2 
was used from a previously opened bottle. This is because SmI2 has been known to react 
vigorously with the diradical O2. Although extreme care was taken to always open bottles and 
transfer SmI2 under an atmosphere of nitrogen gas, it was evident that even trace amounts of O2 
would react with SmI2 in the bottle. This process could be detected by color. A fresh 0.1M 
solution of SmI2 has a very distinct blue color to it, however immediately upon contact with O2, 
the color changes to a pale yellow. To combat the decomposition of the SmI2 reagent under 
storage, Molander’s protocol25 was attempted to generate SmI2 in situ. In a glovebag, Sm metal 
and I2 were combined with THF and allowed to stir under argon. The literature called for a deep 
blue green color in the solution, but even after three days of stirring, the solution was brown with 
a yellow-green precipitate. Although the solution was not the expected color, it was used in a 
benzyloxy cleavage reaction. However, it became apparent that the attempt to synthesize SmI2 
had not been a success. When this reagent was used to affect the benzyloxy removal, TLC 
indicated that no product was formed after three days of stirring at room temperature and the 
starting material remained unreacted.  
 Because the procedure to synthesize SmI2 was not a success, the focus was turned to 
extending the shelf life of the Aldrich SmI2 reagent. Instead of nitrogen, argon was used during 
the opening of the bottles and the dispensing of the reagent. Although the shelf life of the SmI2 
reagent was extended by doing this, there were still problems with the reaction. Chiara’s 
protocol
24
 indicates that the reaction should be stopped when TLC indicates the disappearance of 
all starting material. These reactions were run for as many as three days with TLC still indicating 
the presence of starting material. The low yields could be explained by the fact that the reaction 
was not going to completion. In an attempt to drive the reaction to completion, a reflux in THF 
was run. Although refluxing often drives reactions to completion, it did not work on this 
molecule. These harsh reaction conditions yielded a brown oil that contained no product based 
on TLC and IR.  
 The next attempt to drive the reaction to completion was based on SmI2 research by 
Shabangi.
26
 The cosolvent used with SmI2, in this case, deoxygenated H2O, can have a bearing 
on the reducing power of SmI2. Shabangi determined that the reducing power of SmI2 was the 
greatest when hexamethylphosphoramide (HMPA) was used as the cosolvent. As a modification 
to the Chiara protocol, deoxygenated H2O was replaced by HMPA. Initially, the results appeared 
to be very encouraging as indicated by the total consumption of all starting material (3) based on 
TLC. However, although all of the starting material had been consumed, there were many more 
side products detected, and the overall amount of pure 4 isolated was about the same as in 
previous reactions. It appears that the HMPA made SmI2 too strong a reducing agent to be used 
15 
 
in this reaction. Because this reaction and separation were logistically more difficult to perform, 
the Chiara protocol remains the most effective way to affect the transformation from 3 to 4.  
 Once the benzyloxy protecting group was removed, the focus of the synthesis became 
extending the molecule from the N-1 position. The original reaction extends the molecule in the 
carboxy terminal direction by adding a group which mimics a glycine residue. This 
transformation was initially attempted via a rhodium-catalyzed carbenoid insertion reaction.
27
 
Carbenes are short lived reactive intermediates which have rarely been isolated, however certain 
reactions involving carbenes have been experimentally shown to react preferentially with 
specific bond types. Two of the most common types of bonds that carbenes react with are the 
carbon-carbon double bond, and the nitrogen-hydrogen bond.
22
 This reaction attempted to 
alkylate 4 at N-1 via a carbenoid insertion reaction. One of the most common synthetic methods 
of generating carbenes is the decomposition of diazo compounds. When treated with a catalyst, 
the diazo compound decomposes to form nitrogen gas and a carbene.
22
 In this reaction, ethyl 
diazoacetate was reacted with a rhodium (II) acetate catalyst to generate the carbene, which 
should insert into the N-1 bond of 4 to from the alkylated product (5). This reaction was run in a 
tolulene reflux for two days. The reaction formed four products based on TLC. Separation by 
column chromatography and analysis of each compound brought about the conclusion that none 
of these compounds were 5. Because this reaction is logistically difficult to run, dangerous (diazo 
compounds have been known to explode in the presence of a rhodium catalyst at reflux), and 
inefficient, it was not explored further as a method of transforming 4 to 5.   
 After the carbenoid insertion reaction had failed, the potential reason was found in the 
literature. Research by Davies
28
 explored the relationship between the choice of diazo compound 
and the success of a carbenoid insertion reaction. A discovery was made that many diazo 
compounds have been known to dimerize in the presence of a rhodium catalyst. In one reaction 
involving ethyl diazoacetate, Davies reported that only 10% of the desired insertion product was 
formed, but 67% of the ethyl diazoacetate reagent formed a dimer. Although this reaction was 
not performed on a - lactam, the results still bear significance. Because such a large proportion 
of the reagent formed the undesirable dimers, the yield would be extremely low no matter what 
compound it was reacted with, because there would not be enough monomeric ethyl diazoacetate 
to cause the insertion reaction to occur. Ethyl diazoacetate was reported to be the worst reagent 
to use in this type of insertion reaction for these reasons.
28
 The research also reported that the 
best diazo compound for this type of insertion reaction was a phenyldiazoacetate methyl ester. 
Using this diazoacetate, Davies reported no dimerization products. This research explains why 
the rhodium catalyzed carbenoid insertion reaction did not work when ethyl diazoacetate was 
used. The evidence that phenyldiazoacetate is such an effective reagent for carbenoid insertions 
has potential future implications on this project. 
16 
 
 Because 5 could not be synthesized by the rhodium catalyzed insertion, the focus was 
shifted to the removal of the proton at N-1 and reaction with the electrophile, ethyl bromoacetate. 
The base initially chosen for this task was lithium-hexamethyldisilizane (LiHMDS). LiHMDS 
was generated in situ by the reaction of 1,1,1,3,3,3-hexamethyldisilisane with butyllithium. 
LiHMDS was used to deprotonate 4 at -75
o
 and ethyl bromoacetate was added. The 
electronegative bromine atom withdraws electron density from the carbon that it is attached to. 
This enhances the electrophilicity of that carbon and consequently makes it more susceptible to 
nucleophilic attack. As the literature
29
 had predicted, this reaction was a difficult transformation 
to accomplish. The success of this reaction was inconsistent, and yields were extremely low (10-
20%). In addition, the successful attempts of this reaction never went to completion.  
 Initially, it was proposed that the deprotonation of N-1 was not being completed in these 
reactions. In order for this reaction to occur, N-1 must be in its deprotonated (most nucleophilic) 
form. If it is not fully deprotonated, N–1 will probably not be nucleophilic enough to react with 
ethyl bromoacetate, and product will not be formed. One way this could happen is if the 
generation of LiHMDS in situ did not go to completion. As mentioned above, one of the reagents 
used to generate LiHMDS is butyllithium. Butyllithium has been known to react vigorously with 
H2O molecules present in atmospheric moisture. Because of this, solutions of butyllithium have 
been known to decrease in molarity under storage. If this was the case, the unpredictable nature 
of the reaction may be attributed to it. If the molarity of butyllithium is lower than expected, the 
full amount LiHMDS would not be generated. Consequently, N-1 from 4 would not be fully 
deprotonated and the reaction would not go to completion. For these reasons, the molarity of 
butyllithium was investigated further. 
 The butyllithium used in these reactions was a 1.6 M solution in hexanes from Aldrich. 
The molarity of butyllithium can be determined by titrating it with 2,5-dimethoxybenzyl 
alcohol.
30
 When treated with organolithium reagents, 2,5-dimethoxybenzyl alcohol has been 
observed change from a colorless solution to a red solution when as little as 0.01 mmol 
equivalents of excess organolithium reagent is added.
30
 This titration makes it possible to 
accurately determine the molarity of compounds such as butyllithium. This procedure was done 
previously in the lab by a colleague, and the molarity of the butyllithium solution was 
determined to be 1.07 M. Because this value was a considerable amount lower than the Aldrich 
value of 1.6 M, this titration was performed again on the butyllithium to see if it had undergone 
any further decrease in molarity.  
 A total of three titrations were done with butyllithium reacting with 2,5-dimethoxybenzyl 
alcohol in THF. Based on these titrations, the molarity of the butyllithium reagent was 1.39 M. 
Although this value was lower than the 1.6 M value indicated by Aldrich, it was higher than the 
1.07 M which was previously calculated. Since all calculations in these reactions had been based 
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on a molarity of 1.07, the theory that the molarity had dropped below 1.07 M and detrimentally 
affected the reaction was proven wrong. 
 The butyllithium titration discounted the theory that LiHMDS had not been obtained in 
quantitative yield during its generation in situ. However, since the alkylation reaction had 
yielded product with a very modest rate of success, a new reaction was attempted based on the 
same principles. In an organic synthesis such as this one, an easy way to circumvent this type of 
problem is to use a different base. Based on the literature
31
, sodium hydride (NaH) is a base that 
has been used to deprotonate similar molecules. An alkylation reaction involving 4 and ethyl 
bromoacetate with sodium hydride gave 5 in a 64% yield on its first attempt. Subsequent 
attempts of this reaction were successful, but in lower yields than the original 64% yield. Typical 
reactions using NaH as the base produced 5 in approximately 35-45% yield.  
 The results from the NaH reactions were substantially better than the results when 
LiHMDS was used as the base. In an attempt to further improve yields, the same reaction was 
performed with potassium hydride (KH) as the base. K
+
 is larger than Na
+
, therefore it holds the 
hydride ion more loosely. Because of this, reactions using KH often yield better results. 
However, when KH was used, 5 was isolated, but the yield was slightly lower than the typical 
40% yield of the NaH reaction. To date, the alkylation using NaH as the base continues to be the 
most efficient way to transform 4 into 5.   
 In addition to the alkylation reactions involving ethyl bromoacetate to yield 5, the use of 
ethyl- 2-bromopropionate was originally proposed. As mentioned previously, reaction of 4 with 
ethyl bromoacetate adds a glycine ethyl ester to N-1 to create 5. If this same reaction was done 
with ethyl- 2-bromopropionate, the group added to N-1 would be a methylated derivative of 5 
which mimics an alanine ethyl ester. Both of these compounds would be useful intermediates in 
this synthetic pathway. With either of these compounds, removal of the t-Boc group, and 
coupling of another group in its place would yield a proposed chymotrypsin inhibitor. Enzyme 
testing two compounds which are different only in one functionality such as these two, is an 
important step in this project. If the addition of the methyl group improves the inhibition of 
chymotrypsin, it can be proposed that the methyl group is interacting in the S1' pocket of the 
enzyme.  
 However, to date, this reaction has not been attempted in the lab. The fact that the yields 
of the alkylation reaction using ethyl bromoacetate have been so low indicates the reaction using 
ethyl-2-bromopropionate would not work well. In nucleophilic substitutions, primary alkyl 
halides (ethyl bromoacetate) are much more reactive than secondary alkyl halides (ethyl-2-
bromopropionate).
10
 The reason for this is explained by the mechanism of these reactions. When 
the nucleophile (N-1) attacks the electrophilic carbon on the alkyl halide, the bond between N-1 
and the electrophilic carbon is being formed as the bond between the bromine atom and the 
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electrophillic carbon is being simultaneously broken. The transition state of this reaction 
involves five groups being attached to the electrophilic carbon.
10
 In the primary alkyl halide, two 
of these five groups are hydrogen atoms. Since the hydrogen atoms don’t occupy much space, 
there is not a great deal of steric hindrance in the transition state, and the reaction occurs easily. 
In the case of a secondary alkyl halide such as ethyl-2-bromopropionate, one of the hydrogen 
atoms has been replaced with a methyl group. This methyl group is much larger than the 
hydrogen atom which it replaced, and it adds steric hindrance to the transition state, making it a 
higher energy intermediate. This increases the activation energy needed to reach the transition 
state, and cause the reaction to proceed. In many cases, the energy level of the transition state is 
too high to be overcome, and the reaction does not occur.
10
 If the ethyl bromoacetate reaction 
had worked in high yield, this reaction would be attempted to produce another group of 
compounds for enzyme inhibition. 
 Once 5 had been synthesized, the next step in Scheme 2 was to remove the tert- 
butoxycarbonyl protecting group, and couple various residues to the nitrogen atom to yield 
potential chymotrypsin inhibitors. As was mentioned previously, the t-Boc group removal from 3 
was not possible because the benzyloxy substituent at N-1 made the -lactam susceptible to ring 
opening. This factor was not a problem with 5, as the t-Boc removal proved to be a rapid and 
facile reaction. The reagent used for this transformation was trifluoroacetic acid (TFA) in dry 
dichloromethane (1:2 ratio). TFA is perhaps the most universal reagent in t-Boc removal 
reactions.
32
 TFA protonates the oxygen atom from the carbamate, which subsequently 
decomposes to form the free amine (6) along with 2- methylpropene and CO2 as side products.
10
 
Occasionally, an alcohol such as p-cresol is used to scavenge for liberated t-butyl cations 
produced by the reaction,
32
 but it was found to be unnecessary in this case. The reaction of 5 with 
TFA in CH2Cl2 produced 6 in quantitative yield after one hour of stirring at room temperature. 
The success of this reaction is easily determined by 
1
H NMR. The 
1
H NMR spectrum of 5 has a 
very large singlet peak at 1.41 ppm which represents the nine hydrogen atoms associated with 
the t-Boc group. If the reaction successfully yields 6, the 
1
H NMR spectrum will be missing this 
signature peak, a telltale sign that the reaction was a success.  
 The extension of 6 from the free amine, would yield a potential peptidomimetic 
chymotrypsin inhibitor. To date, three different reactions of this type have been attempted, but 
have not met with satisfactory results. The first attempt was to acetylate the free amine to yield 7. 
Due to the small amount of 6 available at that time, this appeared to be easier than running a 
coupling reaction with another amino acid residue. In addition, the acyl group would accomplish 
two more things: it would protect the free amine, which is known to be a very reactive species 
and it would add another carbonyl group which would cause the molecule to more closely 
resemble a peptide; this would increase the probability of 7 being recognized by chymotrypsin in 
19 
 
an enzyme assay. This transformation was attempted by reacting 6 with acetic anhydride. After 
aqueous work-up, TLC indicated that all 6 had been consumed, and many side products had 
formed. After separation by flash chromatography, none of these compounds isolated appeared 
to be product.  
 The next attempt to elaborate on 6 was to couple it to N-acetyl-phenylalanine. The 
addition of phenylalanine would increase the peptidomimetic character of the molecule which 
would enhance its chance of being recognized by chymotrypsin in an enzyme assay. More 
importantly, the addition of phenylalanine would introduce an aromatic phenyl group into the 
molecule. As mentioned previously, the phenyl group is a common recognition element for 
chymotrypsin. This fact, along with the background information previously developed, indicates 
that 8 would potentially be a good competitive inhibitor of chymotrypsin. As was the case with 
the attempted synthesis of 7, this reaction was logistically difficult to perform on such a small 
scale. The intricate coupling reaction involving N-N-disopropylethylamine, 
hydroxybenzotriazole (HOBT) and EDC, did not conclusively yield any measurable amount of 8. 
Due to the small scale on which this reaction was performed, the result was inconclusive. If a 
slightly larger quantity of 6 was available to run this reaction on, a conclusive determination of 
its success could be obtained. 
 The other attempted reaction was to transform 6 into its N-Cbz (benzyloxycarbonyl) 
derivative (9). The addition of the benzyloxycarbonyl group would add the phenyl group to the 
molecule as a potential chymotrypsin recognition element. This reaction was chosen because 
there was only a small amount of 6 available, and this reaction had proven to be easier based on 
work of a colleague in the lab. TLC upon completion of this reaction indicated that a product had 
formed that was less polar than the starting material. Infrared spectroscopy indicated that the -
lactam is most likely still intact, and that an aromatic group is present within the molecule. 
However, before this molecule can be tested in a chymotrypsin assay, it will have to be sent to 
the University of New Hampshire for 300 MHz 
1
H NMR testing. Once the 300 MHz 
1
H NMR 
data from UNH becomes available, the purity of -lactam 9 can be determined. If this compound 
is found to be pure 9, then it will be immediately tested in a chymotrypsin assay.   
 Recently, scheme 3 has also been explored as a method for generating a different 
inhibitor. Scheme 3 is identical to scheme 1, with the exception that the N-protecting group used 
is a benzyloxycarbonyl (Cbz) instead of a tert-Butoxycarbonyl group. All reactions are run under 
the same conditions as in scheme 1, but the final product is the Cbz-protected -lactam 12. It is 
proposed that this compound may inhibit chymotrypsin based on its structure. It has an extended 
structure similar to a peptide, the -lactam core has been established, and two phenyl groups are 
present as potential recognition elements for chymotrypsin. This compound can be made in a 
facile three step synthesis, and could be beneficial in the development of the enzyme assay 
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techniques. The reason that this scheme is not a major focus of this project is because -lactam 
12 is a synthetic dead end in this pathway. -lactam 12 is protected at its N-terminus by a  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3: Benzyloxycarbonyl Protected -lactam  
 
benzyloxycarbonly (Cbz) group, and at its C-terminus by an O-benzyloxy (OBn) protecting 
group. The next step in the synthesis would be to remove one of these protecting groups and  
extend the molecule in that direction. Unfortunately, these two protecting groups are both 
removed under the same conditions, and there are currently no synthetic methods available to 
distinguish between them when they are present in the same molecule. Hydroxamate 10 and 
mesylate 11 have been synthesized by scheme 3. Currently, the transformation of mesylate 11 to 
-lactam 12 is being performed in the lab. Once this compound is isolated and tested for purity, 
it will be tested in a chymotrypsin assay.    
 
Conclusions and Future Directions 
 Enzyme assays of the preliminary inhibitors (9 and 12) will provide useful information 
about the utility of -lactam peptidomimetics as serine protease inhibitors. In order to better 
understand how these inhibitors work and obtain a pharmacophore, the library of potential 
inhibitors must be expanded. This will be accomplished by continuing to follow schemes 1 and 
2. In order to improve the efficiency of scheme 2, some new reaction conditions have been 
proposed. 
 First, as an alternative to the SmI2 reaction, the N-O reduction could be achieved by 
reacting -lactam 3 with a solution of sodium in ammonia at low temperature. Previous work by 
Floyd et al
33
 has shown these reaction conditions to be effective for the reduction of N-O bonds 
attached to - lactams. Floyd’s group used these conditions to yield the reduced product in 
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essentially quantitative yield. However, the bond that Floyd’s group was reducing was an N-
OCH3 bond, not an N-OBn bond like the one in -lactam 3. The effect that the benzyl group will 
have on this transformation will have to be determined experimentally. However, if this reaction 
occurs in high yield, it will replace the SmI2 reduction in scheme 2.  
 Although the alkylation of -lactam 4 to yield -lactam 5 has been achieved with some 
degree of success with NaH as the base, recent findings in the literature
34,35
 indicate that Cs2CO3 
may be a more effective base. Both Gala
34
 and Palomo
35
 have reported satisfactory results in N-
alkylations of -lactams when Cs2CO3 is used as the base. In the future, Cs2CO3 will be used in 
the transformation of 4 to 5. If the yields are higher and more consistent than in previous 
attempts with NaH, then, Cs2CO3 will be permanently incorporated into scheme 2.    
 The N-alkylation reactions in this pathway lead to a glycine mimic attached to N-1 of the 
- lactam. As previously mentioned, other alkylating agents (such as ethyl-2-bromopropionate) 
will not react at N-1 due to steric hindrance in the transition state. Because of this, the utility of 
the N-alkylation step is limited in that it can only add a glycine residue to the -lactam core. Two 
other methods (figure 6) will be explored to alkylate N–1 under different conditions. Once these 
compounds are synthesized, their t-Boc groups can be removed, and other residues can be 
coupled to the amine by using the reactions from scheme 2. Inhibition assays of these different 
compounds will hopefully provide insight on the binding affinity of chymotrypsin, and lead to 
the development of a pharmacophore.   
 
 
 
 
 
 
 
 
 
 
Figure 6: Alternatives to the N-Alkylation Using Ethyl Bromoacetate  
    
 Based on the work of Shah et al
36
, isocyanates can be used to N-alkylate -lactams. The 
reaction of -lactam 4 with the isocyanate shown in figure 6 and triethylamine, would yield -
lactam 13. This molecule would not directly mimic a peptide, but it would incorporate an 
additional carbonyl group, and an ethyl group which could possibly interact in a hydrophobic 
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pocket of chymotrypsin. This reaction should be an easier alternative to the difficult N-alkylation 
using ethyl bromoacetate based on the results of Shah et al.
36
  
 As mentioned previously, research by Davies
28
 has indicated that phenyldiazoacetate 
methyl ester is an excellent reagent for a rhodium catalyzed carbenoid insertion reaction. 
Reaction of - lactam 4 with phenyldiazoacetate methyl ester in the presence rhodium (II) 
acetate would yield - lactam 14 (figure 6). The product of this reaction does not directly mimic 
a peptide, but it does have a carbonyl group, a phenyl group, and a methyl group, all which could 
be recognized by chymotrypsin in an assay. In order to perform this reaction, a method to make 
phenyl diazoacetate methyl ester would need to be ascertained.  
 In addition to this, another goal is to produce 100 mg of each compound involved in 
schemes 1,2, and 3. Obtaining 100 mg of each product in purified form will allow these 
molecules to be subjected to further analysis of their purity. In order to prove that each 
compound has been obtained, these molecules have to be sent out for elemental analysis and 
13
C 
NMR. This information, combined with 
1
H NMR, IR, melting points, and TLC data will 
determine the exact structure of each intermediate in this synthesis. 
  
Experimental Section 
General: Infrared spectra were recorded on a Bio-Rad FTS-7 Infrared Spectrometer with CH2Cl2 
as the solvent. All 
1
H NMR experiments were recorded on a Varian T-60 NMR Spectrometer in 
CDCl3 unless otherwise noted. (Some of the more important molecules were tested on a 300MHz 
NMR spectrometer from the University of New Hampshire). TLC experiments were performed 
on Aldrich General Purpose TLC Plates-Silica on Glass with a UVP Short Wave Ultraviolet 
Lamp (254nm), ninhydrin (solution in butyl-alcohol) and I2 as detection methods. All column 
chromatography separations were performed with Aldrich Silica Gel (200-400 mesh). All 
melting points were recorded on a Thomas Hoover Uni-Melt Capillary Melting Point Apparatus. 
Hydroxamate (1): 2000 mg (9.74mmol) of N-tertButoxycarbonyl-L-serine was dissolved in 10 
mL THF: 20mL H2O. Then 2333mg of O-Benzylhydroxylamine-hydrochloride (14.61mmol) 
was added. An additional 4mL (minimum amount) of THF was added to dissolve the remaining 
O-Benzylhydroxylamine-hydrochloride. The pH of the solution was 1.75. 3M NaOH was added 
until the pH was 4.46. 2333 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride was dissolved in H2O, and added to the stirring solution. To combat the climb in 
pH, 1M HCl was periodically added to maintain a pH range of 4-5. After 2 hours, the product 
was collected by vacuum filtration, and dried in a 110
o
C oven. The product was recrystallized in 
ethyl acetate and hexanes to give 2654 mg of the white crystalline hydroxamate 1: mp 129.5-
131
o
C (literature value
20
 130-131
o
C).  TLC: Rf 0.51 in ethyl acetate. 
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Mesylate (2): Under argon, 1.07mL (13.88mmol) of methanesulfonyl chloride was added to a 
stirred solution of 2 (3550mg, 11.57mmol) in 20mL dry pyridine at 0
o
C. After 2 hours at 0
o
C, the 
reaction pot was warmed to room temperature. Ethyl acetate was added, and the organic layer 
was washed with 1M HCl until the aqueous wash was acidic to pH paper. The organic layer was 
then washed with brine, dried over MgSO4, filtered, and concentrated in vacuo to obtain 
mesylate 3 as an oil ( 4195mg 94% yield).  TLC: Rf .73 in ethyl acetate. 
 
-lactam (3): Under argon, 565 mg (4.063mmol) of K2CO3 was dissolved in 20mL dry acetone 
and brought to a reflux. 526mg of 2 was dissolved in 10mL dry acetone and added to the 
refluxing solution. After 2.5 hours, the reaction was cooled to room temperature, and filtered 
through celite. The reaction mixture was then concentrated to obtain a yellow oil which was 
dissolved in ethyl acetate and washed one time each with 1M HCl, 1M NaHCO3, and brine. The 
ethyl acetate layer was dried over MgSO4 and concentrated to yield a yellow oil. The oil was 
purified on a silica column with a 1/3 ethyl acetate/hexanes mobile phase. Fractions from the 
column were collected, concentrated, and recrystallized in ethyl acetate and hexanes to yield 
294mg (75% yield) of 3 as a white crystalline solid: mp 89.5-91
o
C (literature value
21
 91-92
o
C). 
TLC: Rf 0.56 in 2:1 ethyl acetate: hexanes, Rf 0.26 in 1:3 ethyl acetate: hexanes. 
1
H NMR 
(60MHz, CDCl3): 7.40(s,5H); 5.23(s,1H; 4.95(s,2H); 4.36(s,1H); 3.45(t, J=2Hz, 1H); 3.23-
3.08(m,1H); 1.41(s,9H).  IR (CH2Cl2): 3433, 2900, 1779, 1723, 1518 cm
-1
 
 
-lactam (4): Under argon, 30mL (2.97mmol) of SmI2 was combined with 0.40mL of 
deoxygenated water. Then 290mg of 3 was dissolved in THF and added to the reaction pot. After 
42 hours, the reaction was partitioned between saturated NaHCO3 and ethyl acetate. The aqueous 
layer was extracted three times with ethyl acetate. The combined organic extracts were washed 
once each with 10% Na2S2O3 and brine, dried over MgSO4, and concentrated to yield a white 
solid which was purified on a silica column with 2/1 ethyl acetate/hexanes as the mobile phase. 
-lactam 4 was isolated as a white solid (72mg, 42% yield). mp 173-174oC (literature value24 
173-174
o
C). TLC Rf 0.13 in 2/1 ethyl acetate/hexanes. 
1
HNMR (300MHz, CDCl3): 5.85(s,1H); 
5.17(s,1H); 4.84(s,1H); 3.63(t,1H); 3.35-3.30(m,1H); 1.43(s,9H). IR(CH2Cl2): 3400, 1779, 1716, 
1513 cm
-1
. 
 
-lactam (5): Method A: Under nitrogen, 0.106mL (0.503mmol) of 1,1,1,3,3,3- 
Hexamethyldisilizane was dissolved in THF and cooled to -75
o
C in a dry ice/acetone bath. 
0.32mL of butyllithium (1.07M solution, 0.503mmol) was added, and the solution was stirred at 
-75
o
C for 15 minutes to yield 0.443mmols of lithium-hexamethyldisilizane (LiHMDS) in situ. -
lactam 4, (35mg 0.201mmol) was added to the stirring solution of LiHMDS at -75
o
C. 0.247mL 
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(0.233mmol) of ethyl bromoacetate was added via syringe. The reaction was run at -75
o
C for 1 
hour, then it was warmed to room temperature and stirred until TLC indicated consumption of all 
starting material (2 hours at room temperature. The reaction pot was partitioned between 
dichloromethane and deionized water. The aqueous layer was extracted twice with 
dichloromethane. The combined dichloromethane extracts were washed once with brine, dried 
over MgSO4, and concentrated to yield 59 mg of a yellow oil. The oil was purified by flash 
chromatography with a 2/1 ethyl acetate/hexanes mobile phase to yield 10mg of 5 as a white 
solid (64% yield). TLC: Rf 0.43 in 2/1 ethyl acetate/hexanes. 
1
HNMR (300MHz, CDCl3): 
5.15(s,1H); 4.93(s, 1H); 4.20(q, J=7.2Hz, 2H); 4.05(s, 2H); 3.75(t, J=6.6Hz, 1H); 3.43-3.40(m, 
1H); 1.45(s, 9H). IR(CH2Cl2): 3437, 2597, 1775, 1721, 1508 cm
-1
. 
 
Method B: Under argon, 31mg of 4 (0.176mmol) was dissolved in 5mL of THF. Then 18mg 
(0.445mmol) of sodium hydride (60% dispersion in mineral oil) was washed with hexanes and 
added to the reaction pot at 0
o
C. After 15 minutes, 0.0217ml (0.196mmol) of ethyl bromoacetate 
was added via syringe. The reaction was allowed to warm to room temperature. After 2 hours, 
TLC still indicated presence of starting material. An additional 0.01ml of ethyl bromoacetate was 
added. After 1 additional hour at room temperature, the THF volume was concentrated to 3 mL, 
and the reaction pot was partitioned between ethyl acetate and saturated NH4Cl. The aqueous 
layer was extracted twice with ethyl acetate. The combined organic extracts were then washed 
once with brine, dried over MgSO4, and concentrated to obtain 29mg of a yellow oil (64% crude 
yield). TLC: Rf 0.44 in 2:1 ethyl acetate/hexanes, Rf 0.20 in 1:1 ethyl acetate/hexanes, Rf 0.38 in 
5% methanol: dichloromethane. 
1
HNMR (60 MHz, CDCl3) 5.15(s,1H); 4.93(s, 1H); 4.20(q,2H); 
4.05(s, 2H); 3.75(t, 1H); 3.43- 3.40(m, 1H); 1.45(s, 9H). IR(CH2Cl2): 3437, 2597, 1775, 1721, 
1508 cm
-1
. 
 
Method C: The protocol was identical to that of method B with the exception that potassium 
hydride (KH) was used as the base as opposed to sodium hydride. Column chromatography 
yielded 5 as a clear oil. TLC: Rf 0.43 in 2/1 ethyl acetate/hexanes. 
1
HNMR (60 MHz, CDCl3) 
5.15(s,1H); 4.93(s, 1H); 4.20(q,2H); 4.05(s, 2H); 3.75(t, 1H); 3.43-3.40(m, 1H); 1.45(s, 9H). 
IR(CH2Cl2): 3437, 2597, 1775, 1721, 1508 cm
-1
. Inconclusive % yield.  
 
-lactam (6): Under argon, 16mg (0.062mmol) of 5 was dissolved in 2 mL of dry 
dichloromethane and cooled to 0
o
C. Trifluoroacetic acid, 0.25 mL was added and the solution 
was warmed to room temperature and stirred for 1 hour. After 1 hour, TLC indicated that the 
starting material had been consumed, and a much more polar product had been formed. The 
reaction pot was cooled to 0
o
C and quenched with saturated NaHCO3. Then, the solution was 
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partitioned between dichloromethane and saturated NaHCO3. The aqueous layer was removed, 
and the organic layer was washed once each with saturated NaHCO3 and brine, dried over 
Na2SO4, and concentrated to yield10 mg (100% yield) 6 as a clear oil. TLC: Rf 0.1 in 2/1 ethyl 
acetate/hexanes (with a very distinct orange color in its ninhydrin spot). IR(CH2Cl2): 3437, 2597, 
1760, 1508 cm
-1
.      
 
Hydroxamate (10): 515mg (2.10mmol) of N-benzyloxycarbonyl-L-serine was dissolved in 10 
mL THF: 20mL H2O. Then 500mg of O-Benzylhydroxylamine-hydrochloride (3.14mmol) was 
added. The pH of the solution was 1.3. Then 3M NaOH was added until the pH was 4.5. Then 
508mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride was dissolved in H2O, 
and added to the stirring solution. To combat the climb in pH, 1M HCl was periodically added to 
maintain a pH range of 4-5. After 2 hours, the product was collected by vacuum filtration, and 
dried in a 105
o
C oven. The product was recrystallized in ethyl acetate and hexanes to give 
515mg of the white crystalline hydroxamate 10: mp 125-127
o
C.  TLC: Rf 0.19 in 2:1 ethyl 
acetate/hexanes. 
 
Mesylate (11): Under argon, 0.07mL (0.87mmol) of methanesulfonyl chloride was added to a 
stirred solution of 10 (250mg, 0.725mmol) in 5mL dry pyridine at 0
o
C. After 2 hours at 0
o
C, the 
reaction pot was warmed to room temperature. Ethyl acetate was added, and the organic layer 
was washed with 1M HCl until the aqueous wash was acidic to pH paper. The organic layer was 
then washed with brine, dried over MgSO4, filtered, and concentrated in vacuo to obtain 
mesylate 11 as a white solid ( 274mg 90% yield): mp 106-108
o
C.  TLC: Rf 0.46 in 2:1 ethyl 
acetate/hexanes. 
 
References 
1. Sandler, M.; Smith, H. J., eds. Design of Enzyme Inhibitors as Drugs; Oxford University 
Press, 1998; Powers, J. C.; Zimmerman, M., Section 18C.  
 
2.  Firestone, R.A.; Barker, P.L.; Pisano, J.M.; Ashe, B.M.; Dahlgren, M.E. “Monocyclic -
Lactam Inhibitors of Human leukocyte Elastase” Tetrahedron Letters 1990, 46, 2255. 
 
3. Knight, W.B; Chabin, R.; Green, B. “Inhibition of Human Serine Proteases by Substituted 2-
Azetidinones” Arch. Biochem. Biophys. 1992, 296, 704. 
 
4. Knight, W.B.; Green, B.G.; Chabin, R.M.; Gale, P; Maycock, A.L.; Weston, H.; Kuo, D.W.; 
Westler, W.M.; Dorn, C.P.; Finkle, P.E.; Hagmann, W.K.; Hale, J.J,; Liesch, J.; MacCoss, M.; 
Navia, M.A.; Shah, S.K.; Underwood, D.; Doherty, J.B. “Specificity, Stability, and Potency of 
Monocyclic -Lactam Inhibitors of Human Leukocyte Elastase” Biochemistry 1992, 31, 8160. 
 
26 
 
5. (a) Bulychev, A.; O’Brien, M.E.; Massova, L.; Teng, M.; Gibson, T.A.; Miller, M. J.; 
Mobasherry, S. “Potent Mechanism-Based Inhibition of the TEM-1--Lactamase by Novel N-
Sulfonyloxy - Lactams” J. Am. Chem. Soc. 1995, 117, 5938. (b) Ahuluwalia, R; Day, R.A.; 
Nauss, J.; “A Bifunctional Monocyclic -Lactam Cross-Links Across the Active Site of -
Lactamase” Biochem, Piophys. Res. Comm. 1995, 206 (2), 577. 
 
6. Kuo, D.; Weidner, J.; Griffin, P.; Shah, S.K.; Knight, W.B. “Determination of the Kinetic 
Parameters of Escherichia Coli Leader Peptidase Activity Using a Continuous assay: The pH 
Dependance and Time-Dependant Inhibition by -Lactams Are Consistent with a Novel Serine 
Protease Mechanism” biochemistry 1994, 33, 8347. 
 
7. (a) Yoakim, C.; Ogilvie, W. W.; Cameron, D.R.; Chabot, C.; Guse, L.; Hache, B.; Naud, J.; 
O’Meara, J.A.; Plante, R.; Deizel, R. “-Lactam Derivatives as Inhibitors of Human 
Cytomegalovirus Protease” J. Med. Chem. 1989, 41, 2882.  (b) Yoakim, C.; Ogilvie, W. W.; 
Cameron, D.R.; Chabot, C.; Guse, L.; Hache, B.; Naud, J.; O’Meara, J.A.; Plante, R.; Deizel, R. 
“Potent -Lactam Inhibitors of Human Cytomegalovirus Protease” Antivir. Chem. Chemother. 
1998, 9 (5), 379.  (c) Bonneau, P.R.; Hasani, F.; Plouffe, C.; Malenfant, E.; LaPlante, S.R.; Guse, 
I.; Ogilvie, W.W.; Plante, R.; Davidson, W.C.; Hopkins, J.L.; Morelock, M.M.; Cordingley, 
M.G.; Deizel, R. “Inhibition of Human Cytomegalovirus Protease by Monocyclic -Lactam 
Derivatives: Kinetic Characterization Using a Fluorescent Probe” J. Am. Chem. Soc. 1999, 121, 
2965.  
 
8. Although chymotrypsin has not been implicated with any of these ailments, it has been the 
most well studied serine protease. In addition, it is easy to use, and easily attainable from 
chemical companies. Since serine proteases react via the same pathway, concepts developed 
from this project may be applied to the design of inhibitors of other members of the serine 
protease family. 
 
9. This refers to the terminology originally proposed by L. Schechter and A. Berger (Biochem. 
Biophys. Res. Commun. 1967, 27, 157). The S1, S2,etc refer to the enzyme subsites that 
correspond to P1, P2, etc of the amino acid residues of the substrate, or inhibitor in this case. The 
subscript numbers increase from the scissile bond in the direction of the amino terminus. S1', S2', 
etc and P1'. P2', etc are the subsites and residues respectively, that proceed in the direction of the 
carboxy terminus beginning from the scissile bond. 
 
10. Ege, Seyhan Organic Chemistry: Structure and Reactivity- Third Edition copywrite 1994, 
D.C. Heath and Company, Lexington, Massachusetts 
 
11. (a) Green, B.G.; Chabin, R.; Mills, S.; Underwood. D.J.; Shah, S.K.; Kou, D.; Gale, P.; 
Maycock, A.L.; Leisch, J.; Burgey, C.S.; Doherty, J.B.; Dorn, C.P.; Finke, P.E,; Hagmann, 
W.K.; Hale, J.J.; MacCoss, M.; Westler, W.M.,; Knight, W.B. “Mechanism of Inhibition of 
Human Leukocyte Elastase by -Lactams. 2. Stability, Reactivation Kinetics, and Products of -
Lactam Derived E-I Complexes” Biochemistry 1995, 34, 14331. (b) Taylor, P.; Anderson, V.; 
Dowden, J.; Flitsch, S.L.; Turner, N.J.; Loughran, K.; Walkinshaw, M.D.; “Novel Mechanism of 
Inhibition of Elastase by -Lactams is Defines by Two Inhibitor Crystal Complexes” J. Biol. 
Chem. 1999, 274 (35), 24901. 
27 
 
 
12. Underwood, D.J.; Green, B.G.; Chabin, R.; Mills, S.; Doherty, J.B.; Finkle, P.E.; MacCoss, 
M.; Shah, S.K.; Burget, C.S.; Dickinson, T.A.; Griffin, P.R.; Lee, T.E.; Swiderek, K.M.; Covey, 
T.; Westler, W.M.; Knight, W.B.; “Mechanism of Inhibition of Human Leukocyte Elastase by -
Lactams. 3. Use of Electrosptray Ionization Mass Spectrometry and Two-Dimensional NMR 
Techniques to Identify -lactam-Derived E-I Complexes” Biochemistry 1995, 34, 14344. 
 
13. (a) Thompson, R.C.; Bauer, C.A. “Reaction of Peptide Aldehydes with Serine Proteases. 
Implications for the Entropy Changes Associated with Enzymatic Catalysis” Biochemistry 1979, 
18, 1552. (b) Thompson, R.C. “Use of Peptide Aldehydes to Generate Transition-State Analogs 
of Elastase” Biochemistry 1973, 12, 47. (c) Kawamure, K.; Kondo, S.; Maeda, K.; Umezawa, H, 
“Structure and Synthesis of Leupeptins Pr-LL and Ac-LL” Chem. Pharm, Bull 1969, 17, 1902. 
 
14. (a) Bone, R.; Shenvi, A.B.; Kettner, C.A.; Agard, D.A. “Serine Protease Mechanism: 
Structure of an Inhibitory Complex of -Lytic Protease and a Tightly Bound Peptide Boronic 
Acid” Biochemistry 1987, 26, 7609. (b) Lindquist, R.N.; Terry, C. “Inhibition of Subtilisin by 
Boronic Acids, Potential Analogs of Tetrahedral Reaction Intermediates” Arch. Biochem. 
Biophys. 1974, 160, 135. 
 
15. (a) Tuhy, P.M; Powers, J.C. “Inhibition of Human Leukocyte Elastase by Peptide 
Chloromethylketones” FEBS Lett. 1975, 50, 359. (b) Powers, J.C.; Gupton, B.F.; Harley, A.D.; 
Nishino, N.; Whitley, R.J. “Specificity of Porcine Pancreatic Elastase, Human Leukocyte 
Elastase, and Cathepsin G. Inhibition with Peptide Chloromethyl Ketones” Biochem. Biophys. 
Acta. 1977, 485, 158. 
 
16. (a) Imperiali, B.; Aberles, R.H. “Inhibition of Serine Proteases by Peptidyl Fluoromethyl 
Ketones” Biochemistry 1986, 25, 3760. (b) Skiles, J.W.; Fuchs, V.; Miao, C.; Sorcek, R.; 
Grozinger, K.G.; Maudlin, S.C.; Vitous, J.; Mui, P.W.; Jacober, S.; Chow, G.; Matteo, M.; 
Skoog, M.; Weldon, S.M.; possanza, G.; Keirns, J.; Setts, G.; Rosenthal, A.S. “Inhibition of 
Human Leukocyte Elastase (HLE) by N-Substituted Peptidyl Trifluoromethyl Ketones” j. Med 
Chem. 1992, 35, 641. (c) Imperali, B.; Abeles, R.H. “Extended Binding Inhibitors of 
Chymotrypsin That Interact with Leaving Group Subsites S1'-S3' ” Biochemistry 1987, 26, 4474. 
 
17. (a) Mehdi, S.; Angelastro, M.R.; Burkhart, J.P.; Koehl, J.R.; Peet, N.P.; Bey, P. “The 
Inhibition of Human Neutrophil Elastase and Cathespin G by Peptidyl 1-2 Dicarbonyl 
Derivatives” Biochem. Biophys. Res. Commun. 1990, 166, 595. (b) Peet, N.P. Burkhart, J.P.; 
Angelastro, M.R.; Giroux, E.L.; Mehdi, S.; Bey, P.; Kolb, M.; Neises, B.; Schirlin, D. “Synthesis 
of Peptidyl Flouromethyl Ketones and Peptidyl -Keto Esters as Inhibitors of Porcine Pancreatic 
Elastase, Human Neutrophil Elastase, and Rat and Human Neutrophil Cathepsin G.” J. Med. 
Chem. 1990, 33, 394. 
 
18. (a) Powers, J.C.; Gupton, B.F. “Reaction of Serine Proteases With Aza-amino acid and Aza-
peptide Derivatives” Met. Enzymol. 1977, 46, 208. (b) Baggio, R.; Shi, Y.Q.; Wu, Y.Q.; Abeles, 
R.H. “From Poor Substrates to Good Inhibitors: Design of Inhibitors for Serine and Thiol 
Proteases” Biochemistry 1996, 35, 3351.  
 
28 
 
19. (a) Linder, M.R.; Podlech, J. “Synthesis of Peptidomimetics Containing a -Lactam Moiety 
Using Peptidic Diazoketones and Imines in a Staudinger Reaction” Org. Lett. 1999, 1, 869. (b) 
Palomo, C.; Aizupura, J.M.; Benito, A.; Galarza, R.; Khamrai, U.K.; Vazquez, J.; de Pascual-
Teresa, B.; Neito, P.M.; Linden, A. “A-alkyl--Amino--Lactam Peptides: Design, Synthesis, 
and Conformational Features” Agnew. Chem. Int. Ed. 1999, 38, 3056. 
 
20. Miller, M.J.; Mattingly, P.G.; Morrison, M.A.; Kerwin, J.F. Jr. “Synthesis of -Lactams from 
Substituted Hydroxamic Acids” J. Am. Chem. Soc. 1980, 102, 7026-7032. 
 
21. Floyd, D.M; Fritz, A.W.; Pluscec, E. R.; Cimarusti, C.M. “Monobactams. Preparation of (S)-
3-Amino-2-oxyazetidine-1-sulfonic Acids from L-a-Amino-b-hydroxyl Acids via Their 
Hydroxamic Esters”  J. Org. Chem., 1982 vol. 47 (26), 5160-5167 
 
22. March, Jerry Advanced Organic Chemistry: Reactions, Mechanisms, and Structure- Fourth 
Edition copywrite 1992, John Wiley and Sons, New York 
 
23. Hannesian, S.; Coutre, C.; Wyss, H. “Design and Reactivity of Organic Functional Groups-
Utility of Imidazoylsulfonates in the Synthesis of Monobactams and 3-Amino Noncardicinic 
Acid” Can. J. Chem. 1985 Vol 63, 3613-3617 
 
24. Chiara, J.L.; Destabel, C.; Gallego, P.; Contelles, J.M. “Cleavage of N-O Bonds Promoted by 
Samarium Diiodide: Reduction of Free or N-Acetylated O-Alkylhydroxylamines” J. Org. Chem. 
1996, (61), 359-360 
 
25. Molander et al J Org Chem 1999 Vol. 64, (11), 4121 
 
26. Shabangi, M.; Scaley, J.M.; Fuchs, J.R.; Flowers, R.A. “The Effect of Cosolvent on the 
Reducing Power of SMI2 in Tetrahydrofuran” Tetrahedron Letters 1998 (39), 4429-4432 
 
27. Miller, M.J.; Mattingly, P.G. “Synthesis of 2-Azetidinones from Serinehydroxamates: 
Approaches to the Syntheis of 3- Aminononcardicinic Acid” J. Org. Chem. 1981, Vol. 46, No 8, 
1557-1564  
 
28. Davies, H.M..; Hodges, M.; Matari, J.J.; Hansen, T.; Stafford, D.G.; “ Effect of Carbenoid 
Structure on the Reactivity of Rhodium-Stabilized Carbenoids” Tetrahedron Letters 1998 (39), 
4417- 4420 
 
29. Kametani, T. Ihara, M.; Nakayama, A.; Fukumoto, K. “Synthesis of Oxapenem Derrivatives 
by Novel Reductive Cyclization” Tetrahedron Letters 1982 (38), 2489-2504 
 
30. Winkle, M.R.; Lansinger, J.M.; Ronald, R.C. “2,5-dimethoxybenzyl alcohol: a Convenient 
Self-indicating Standard for the Determination of Organolithium Reagents” J.C.S. Chem Comm 
1980 
 
31. Hayashi et al J. Med. Chem. 1998, vol. 41 (3), 2532 
 
29 
 
32. Greene, T.W.; Wuts, P.G. Protective Groups in Organic Synthesis: Second Edition copywrite 
1991 John Wiley and Sons, New York 
 
33. Floyd, D.M.; Fritz, J.P.; Weaver, E.R.; Cimarusti, C.M. “Monobactams. Prepatation of (S)-3- 
Amino-2-oxazetidine-1-sulfonic Acids from L--Amino--hydroxy Acids via Their Hydroxamic 
Esters” J. Org. Chem. 1982, 47, 5160-5167 
 
34. Gala, D.; Steinman, M.; Jaret, R.S. “Tetrahydropyran as an Efficient Alcohol Protecting 
Group for the Synthesis of Penems: Synthesis of Sch 34343" J. Org Chem. 1986, 51, 4488-4490 
 
35. Palomo, C.; Aizpura, J.M.; Benito, A.; Galarza, R.; Khamrai, U.K.; Vazquez, J.; de-Pascual-
Teresa, B.; Neito, P.M.; Linden, A. “-Alkyl--Amino--Lactam Peptides: Design, Synthesis, 
and Conformational Features” Angew. Chem. Im. Ed. 1999, 38, No.20 3056-3058 
 
36. Shrenik, K.S.; Conrad, P.D. Jr.; Finke, P.E.; Hale, J.J.; Hagmann, W.K.; Brause, K.A.; 
Chandler, G.O.; Kissinger, A.L.; Ashe, B.M.; Weston, H.; Knight, W.B.; Maycock,A.L.; Della, 
P.S.; Fletcher, D.S.; Hand K.M., Mumford, R.A.; Underwood, D.J.; Doherty, J.D. “Orally Active 
-Lactam Inhibitors of Human Leukocyte Elastase-1. Activity of 3,3-Diethyl-2-azetidinones” J. 
Med. Chem. 1992, 35, 3745-3754  
 
          
